相关实验视频
Updated: Jan 16, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.3K
在口服抗凝剂相关的内出血中,四因子原素复合缩剂的施用时间
Michael Scott1,2, Jennifer Schultheis1, Shawn Kram1
1Duke University Hospital, Durham, NC, USA.
Hospital pharmacy
|September 29, 2025
概括
对口服抗凝剂相关的内出血 (ICH) 快速服用4因子前列红素复合缩物 (4F-PCC) 并没有影响结果. 4F-PCC的使用时间与血液瘤扩张或48小时内死亡率无关.
科学领域:
- 神经学 神经学
- 血液学 血液学 血液学
- 紧急医疗 紧急医疗
背景情况:
- 口服抗凝剂相关的内出血 (ICH) 携带高发病率和死亡率.
- 建议快速注射静血剂,但最佳时间尚不清楚.
研究的目的:
- 为了确定四因子前列红素复合物缩剂 (4F-PCC) 给药时间 (TTA) 是否会影响OAC相关性ICH患者的血瘤扩张或48小时死亡率.
- 分析4F-PCC TTA对华法林,阿皮克萨班或里瓦罗克萨班使用者的影响.
主要方法:
- 对66名接受4F-PCC治疗的患者进行了回顾性队列研究,用于OAC相关的ICH.
- 根据ICH诊断位置分类的患者:急诊室 (ED),住院或医院外 (OSH).
- 主要结局:血液瘤扩张或在ICH诊断后48小时内死亡.
主要成果:
- 主要结局发生在18名 (27.3%) 患者 (18名血液瘤扩张,0名死亡).
- 血瘤扩张和不扩张的患者之间的4F-PCCTTA没有显著差异 (中位数为107分钟与115分钟,P=.81).
结论:
- 到4F-PCC的时间与OAC相关的ICH中48小时血液瘤扩张或死亡率无关.
- 延迟服用可能会限制4F-PCC的有效性;需要进一步研究最佳时间.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Coagulation
9.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.7K
Venous Thrombosis IV: Nursing Management
201
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
201
Extrinsic and Intrinsic Pathways of Hemostasis
12.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.1K

